[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].

To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases.
A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts.
The cost of pain control per patient is euro 12,515.39 for conventional therapy and euro 5,595.52 for samarium-153 (Quadramet) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust.
Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
AuthorsMaría Velasco Latrás, Luis Carreras Coderch, Fernando Antoñanzas Villar, Juan Coya Viña, José Martín Comín, Francisco Martínez Carderón, José Nieto Martín-Bejarano, Alberto Sáenz Cusí, Gala Serrano Bermúdez, Amaya Echevarría Icaza
JournalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (Clin Transl Oncol) Vol. 7 Issue 5 Pg. 198-204 (Jun 2005) ISSN: 1699-048X [Print] Italy
Vernacular TitleAnálisis coste-efectividad de samario-153 (Quadramet) en el tratamiento del dolor en pacientes con cáncer de próstata y metástasis óseas.
PMID15960931 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Analgesics, Non-Narcotic
  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radioisotopes
  • Samarium
  • samarium Sm-153 lexidronam
  • Adenocarcinoma (drug therapy, economics, secondary)
  • Analgesics, Non-Narcotic (economics, therapeutic use)
  • Bone Neoplasms (drug therapy, economics, secondary)
  • Cost-Benefit Analysis
  • Drug Costs
  • Humans
  • Male
  • Models, Economic
  • Organometallic Compounds (economics, therapeutic use)
  • Organophosphorus Compounds (economics, therapeutic use)
  • Pain Measurement (methods)
  • Prostatic Neoplasms (drug therapy, economics, pathology)
  • Radioisotopes (economics)
  • Samarium (economics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: